New drug aims to protect kidneys in rare disease patients for years
NCT ID NCT03955445
First seen Jan 10, 2026 · Last updated Apr 10, 2026 · Updated 15 times
Summary
This study is testing the long-term safety and effectiveness of a daily oral drug called iptacopan for people with rare kidney diseases (C3G and IC-MPGN). It will follow up to 225 patients who have already been taking the drug in earlier studies, tracking their kidney function and health for up to 14 years. The goal is to see if the drug continues to help control the disease and is safe for long-term use.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for C3 GLOMERULOPATHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-••••
Locations
-
Childrens Hospital Colorado
RECRUITINGAurora, Colorado, 80045, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Col Uni Med Center New York Presby
RECRUITINGNew York, New York, 10032, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Georgia Nephrology Research Inst
RECRUITINGLawrenceville, Georgia, 30046, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Novartis Investigative Site
RECRUITINGCABA, Buenos Aires, C1425AGC, Argentina
-
Novartis Investigative Site
RECRUITINGBuenos Aires, W3400ABH, Argentina
-
Novartis Investigative Site
RECRUITINGBelo Horizonte, Minas Gerais, 30150-221, Brazil
-
Novartis Investigative Site
RECRUITINGPorto Alegre, Rio Grande do Sul, 90035-074, Brazil
-
Novartis Investigative Site
RECRUITINGBotucatu, São Paulo, 3880-1001, Brazil
-
Novartis Investigative Site
RECRUITINGSão Paulo, São Paulo, 04038-002, Brazil
-
Novartis Investigative Site
RECRUITINGSalvador, 40323-010, Brazil
-
Novartis Investigative Site
ACTIVE_NOT_RECRUITINGToronto, Ontario, M5G 2C4, Canada
-
Novartis Investigative Site
RECRUITINGBeijing, 100034, China
-
Novartis Investigative Site
RECRUITINGShanghai, 200040, China
-
Novartis Investigative Site
ACTIVE_NOT_RECRUITINGPrague, 128 08, Czechia
-
Novartis Investigative Site
RECRUITINGMontpellier, 34295, France
-
Novartis Investigative Site
RECRUITINGParis, 75015, France
-
Novartis Investigative Site
RECRUITINGToulouse, 31054, France
-
Novartis Investigative Site
ACTIVE_NOT_RECRUITINGErlangen, 91054, Germany
-
Novartis Investigative Site
RECRUITINGEssen, 45147, Germany
-
Novartis Investigative Site
RECRUITINGHamburg, 20246, Germany
-
Novartis Investigative Site
RECRUITINGMainz, 55131, Germany
-
Novartis Investigative Site
RECRUITINGHeraklion Crete., 715 00, Greece
-
Novartis Investigative Site
RECRUITINGThessaloniki, 546 42, Greece
-
Novartis Investigative Site
RECRUITINGPetah Tikva, 4920235, Israel
-
Novartis Investigative Site
RECRUITINGPetah Tikva, 4941492, Israel
-
Novartis Investigative Site
RECRUITINGRanica, BG, 24020, Italy
-
Novartis Investigative Site
RECRUITINGRoma, RM, 00165, Italy
-
Novartis Investigative Site
ACTIVE_NOT_RECRUITINGNagoya, Aichi-ken, 4668560, Japan
-
Novartis Investigative Site
ACTIVE_NOT_RECRUITINGAsahikawa, Hokkaido, 0788510, Japan
-
Novartis Investigative Site
COMPLETEDSapporo, Hokkaido, 0608543, Japan
-
Novartis Investigative Site
ACTIVE_NOT_RECRUITINGTakatsuki, Osaka, 569 1192, Japan
-
Novartis Investigative Site
RECRUITINGOhtsu, Shiga, 5202192, Japan
-
Novartis Investigative Site
RECRUITINGHachiōji, Tokyo, 193-0998, Japan
-
Novartis Investigative Site
ACTIVE_NOT_RECRUITINGNiigata, 9518520, Japan
-
Novartis Investigative Site
RECRUITINGLeiden, South Holland, 2333 ZA, Netherlands
-
Novartis Investigative Site
RECRUITINGPamplona, Navarre, 31008, Spain
-
Novartis Investigative Site
ACTIVE_NOT_RECRUITINGBarcelona, 08035, Spain
-
Novartis Investigative Site
RECRUITINGMadrid, 28040, Spain
-
Novartis Investigative Site
RECRUITINGMadrid, 28041, Spain
-
Novartis Investigative Site
RECRUITINGSeville, 41009, Spain
-
Novartis Investigative Site
RECRUITINGBern, 3010, Switzerland
-
Novartis Investigative Site
RECRUITINGKöseköy, Kocaeli, 41380, Turkey (Türkiye)
-
Novartis Investigative Site
RECRUITINGKayseri, Melikgazi, 38039, Turkey (Türkiye)
-
Novartis Investigative Site
RECRUITINGAnkara, Yenimahalle, 06500, Turkey (Türkiye)
-
Novartis Investigative Site
RECRUITINGNewcastle upon Tyne, Tyne and Wear, NE7 7DN, United Kingdom
-
Novartis Investigative Site
RECRUITINGCardiff, CF14 4XW, United Kingdom
-
Novartis Investigative Site
RECRUITINGLondon, W12 0HS, United Kingdom
-
University of Iowa Health Care
RECRUITINGIowa City, Iowa, 52242-1091, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Minnesota
RECRUITINGMinneapolis, Minnesota, 55455, United States
Contact Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.